TLDR
Chronic refractory osteomyelitis — bone infection that does not respond to standard antibiotic therapy — is an FDA-approved indication for Hyperbaric Oxygen Therapy (HBOT), covered by Medicare and most PPO insurance plans. HBOT enhances the killing power of antibiotics, directly targets anaerobic bacteria, and stimulates the formation of new blood vessels in infected bone. At OxygenWell in Sherman Oaks and Calabasas, we treat osteomyelitis patients with medical-grade HBOT at up to 2.4 ATA under physician direction.
Table of Contents
- What Is Osteomyelitis?
- Why Chronic Osteomyelitis Resists Standard Treatment
- How HBOT Treats Osteomyelitis
- Clinical Evidence
- Who Qualifies for Insurance-Covered HBOT?
- OxygenWell's Protocol
- Frequently Asked Questions
What Is Osteomyelitis?
Osteomyelitis is an infection of the bone, caused most commonly by Staphylococcus aureus (including MRSA) and, in some cases, anaerobic bacteria. It can arise from direct trauma, surgery, open fractures, diabetic foot infections, or spread hematogenously (through the bloodstream) from another infection site.
Osteomyelitis is classified as:
- Acute: Recent onset, typically responsive to antibiotic therapy and surgical debridement
- Chronic: Persistent or recurrent infection, often with dead bone (sequestra), sinus tracts, and poor vascular supply — making antibiotics alone insufficient
- Chronic refractory: Chronic osteomyelitis that has failed standard antibiotic and surgical management — the specific FDA-approved HBOT indication
Why Chronic Osteomyelitis Resists Standard Treatment
The fundamental problem in chronic osteomyelitis is the same as in diabetic wounds and radiation injuries: oxygen deficiency. Infected bone — especially bone with dead tissue and sinus tracts — has drastically reduced blood flow. Without adequate circulation, two critical events occur:
- Antibiotics cannot penetrate. Most antibiotics reach infected tissue via the bloodstream. In avascular or hypovascular bone, antibiotic concentrations in tissue fall below the minimum inhibitory concentration (MIC) needed to kill bacteria — even when blood levels are therapeutic.
- The immune system fails. Neutrophils — the white blood cells that physically kill bacteria — require oxygen to generate the reactive oxygen species (ROS) used in their antimicrobial oxidative burst. Tissue oxygen levels below 30 mmHg severely impair neutrophil killing capacity.
The result: antibiotics cycle on and off, surgery debrides but cannot fully eradicate the infection, and the bone remains chronically infected for months or years.
How HBOT Treats Osteomyelitis
1. Restores Tissue Oxygenation
By breathing 100% medical-grade oxygen at 2.0–2.4 ATA, HBOT dissolves oxygen directly into plasma, bypassing compromised blood vessels and delivering oxygen to infected bone tissue. A single session raises tissue pO2 from near-zero to 200–400 mmHg in the treatment area. [Hopf HW et al., Wound Repair Regen. 2004]
2. Supercharges Neutrophil Killing Power
With oxygen restored, neutrophils can generate the reactive oxygen species needed to kill bacteria — including MRSA and anaerobes that are notoriously difficult to eradicate. HBOT effectively restores the immune system's front-line defense in infected tissue. [Knighton DR et al., Surgery. 1986]
3. Directly Kills Anaerobic Bacteria
Many bone infections involve anaerobic organisms that thrive in low-oxygen environments. High-dose oxygen is directly bactericidal for anaerobes and bacteriostatic for Staphylococcus aureus, adding a direct antimicrobial action that complements antibiotic therapy.
4. Enhances Antibiotic Efficacy
Certain classes of antibiotics — particularly aminoglycosides — are oxygen-dependent in their mechanism of action. HBOT restores their efficacy in hypoxic infected tissue. Studies show that HBOT combined with antibiotics achieves bactericidal effects in infected bone that neither treatment achieves alone. [Mader JT et al., J Infect Dis. 1980]
5. Stimulates Angiogenesis in Infected Bone
Repeated HBOT sessions trigger VEGF release and new capillary formation in the surrounding tissue, gradually restoring the blood supply that chronic osteomyelitis depends on for long-term resolution.
Clinical Evidence
Mader et al. — Landmark Animal and Clinical Work
Dr. John Mader's foundational research at the University of Texas Medical Branch demonstrated that HBOT combined with antibiotics achieved significantly superior outcomes in chronic osteomyelitis compared to antibiotics alone, establishing the scientific rationale for HBOT as adjunctive therapy. [Mader JT et al., J Infect Dis. 1980]
Davis et al. — Long-Term Outcomes
A clinical series reported in Orthopedics found that patients with chronic refractory osteomyelitis treated with HBOT plus standard surgical and antibiotic management had significantly higher rates of long-term remission compared to historical controls. [Davis JC et al., Orthopedics. 1989]
Undersea and Hyperbaric Medical Society (UHMS) Position
The UHMS — the governing body of hyperbaric medicine — recognizes chronic refractory osteomyelitis as one of its 14 approved indications for HBOT, a designation based on the totality of clinical evidence. This recognition supports Medicare and PPO coverage.
Who Qualifies for Insurance-Covered HBOT?
To qualify for Medicare or PPO coverage for HBOT:
- Diagnosis of chronic refractory osteomyelitis — meaning the infection has failed standard antibiotic and surgical management
- Physician referral from an orthopedic surgeon, infectious disease specialist, or primary care physician
- Documentation of prior failed treatment
OxygenWell handles all insurance verification and pre-authorization. Verify your coverage at oxygenwell.com.
OxygenWell's Osteomyelitis Protocol
Founded and led by Dr. Beth Meneley, DAOM, L.Ac., OxygenWell has delivered over 50,000 HBOT sessions across its Sherman Oaks and Calabasas locations.
- Pressure: 2.0–2.4 ATA
- Session length: 90 minutes
- Frequency: 5 days per week
- Total sessions: Typically 20–40, adjusted to clinical response
- Oxygen: 100% medical-grade, high-flow delivery
HBOT is used as an adjunct to surgical debridement and antibiotic therapy — not as a replacement. Our team coordinates directly with your surgical and infectious disease team.
Frequently Asked Questions
Is HBOT a replacement for antibiotics in osteomyelitis?
No. HBOT is used as an adjunct to standard care — surgery and antibiotics. It enhances their effectiveness and supports tissue recovery, but it does not replace either.
How many HBOT sessions does osteomyelitis treatment require?
Most protocols involve 20–40 sessions, delivered 5 days per week alongside antibiotic therapy. The exact number is determined by the extent of infection, response to treatment, and your surgical team's guidance.
Is HBOT covered by insurance for osteomyelitis?
Yes. Chronic refractory osteomyelitis is an FDA-approved HBOT indication covered by Medicare and most PPO plans. Call OxygenWell at (818) 661-0939 to verify your coverage.
Does HBOT work for MRSA osteomyelitis?
Yes. HBOT restores the oxygen environment in which neutrophils can function and in which oxygen-dependent antibiotics can work — making it particularly valuable in MRSA and other resistant infections. All MRSA cases should be managed with infectious disease specialists; HBOT is an adjunct to that care.
Schedule a Consultation
- Sherman Oaks: 15301 Ventura Blvd., Suite P12, Sherman Oaks, CA 91403
- Calabasas: 23500 Park Sorrento, A2, Calabasas, CA 91302
- Phone: (818) 661-0939
- Website: oxygenwell.com
Written by Dr. Beth Meneley, DAOM, L.Ac. — Founder of OxygenWell. 25+ years in integrative and functional medicine. 12+ years dedicated to hyperbaric medicine in Los Angeles. Over 50,000 HBOT sessions administered under her clinical direction.
